Clinical trial to evaluate the efficacy and safety of two concentrations (1000DPP/ml and 3000DPP/ml) of depigmented polymerized allergen extracts of Depigoid GrassMix / Depigoid FORTE GrassMix compared to placebo, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma due to clinically relevant sensitization to grass pollen - 0600-PG-PSC-218
Latest Information Update: 26 May 2026
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors LETI Pharma GmbH
Most Recent Events
- 12 Apr 2026 New trial record